Search

Search Constraints

You searched for: Author/Creator Bashir, Qaiser

Search Results

31. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high‐dose chemotherapy and autologous stem cell transplantation for lymphoma. Issue 4 (10th February 2017)

32. Phase I study of cord blood‐derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. (14th March 2017)

33. Post‐transplantation cyclophosphamide versus conventional graft‐versus‐host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. (7th March 2016)

34. Predictors of inferior clinical outcome in patients with standard‐risk multiple myeloma. (1st December 2016)

35. Prognostic significance of measurable residual disease in patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation in second or later complete remission. Issue 2 (11th December 2022)

36. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Issue 24 (28th September 2016)

37. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Issue 3 (23rd February 2022)

38. Results of a 2‐arm, phase 2 clinical trial using post‐transplantation cyclophosphamide for the prevention of graft‐versus‐host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Issue 21 (12th July 2016)

39. Short-term cardiac toxicity of autologous hematopoietic stem cell transplant for multiple myeloma. Issue 2 (February 2015)

40. Significance of minimal residual disease monitoring by real‐time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Issue 10 (26th February 2020)